Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Financial Results:
Syngene International Ltd reported Revenues for Q4FY25 of ₹1,018.00 Crores up from ₹917.00 Crore year on year, a rise of 11.01%.
Total Expenses for Q4FY25 of ₹796.00 Crores up from ₹724.00 Crores year on year, a rise of 9.94%.
Consolidated Net Profit of ₹183.00 Crores down 3.17% from ₹189.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹4.55, down 2.99% from ₹4.69 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
